ArticleJournal of immunology (Baltimore, Md. : 1950)2010
CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 66 citations in OpenAlex.
- rs57494551 increases CXCR5 expression and IgMJournal of gastroenterology · 2026Article
- The CXCL13 hub in obesity-related metabolic inflammation: regulation of spatiotemporal heterogeneity and targeted strategies.The Journal of endocrinology · 2026Review
- CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.Diabetologia · 2026Article
- Evaluating Anti-CCL25 as a Therapeutic Strategy to Disrupt Foci Formation in a Spontaneous Murine Model of Sjögren's Disease.International journal of molecular sciences · 2025Article
- Type 1 Diabetes Depends on CD4-Driven Expression of the Transcriptional Repressor Bcl6.Diabetes · 2025Article
- Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.Frontiers in immunology · 2024Review
- Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade.Cancer cell international · 2023Review
- Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023Article
- Tertiary lymphoid structures in autoimmune diseases.Frontiers in immunology · 2023Review
- Footprint of pancreas infiltrating and circulating immune cells throughout type 1 diabetes development.Frontiers in endocrinology · 2023Article
- Intruders or protectors - the multifaceted role of B cells in CNS disorders.Frontiers in cellular neuroscience · 2023Review
- Article
- Lymphotoxins Serve as a Novel Orchestrator in T1D Pathogenesis.Frontiers in immunology · 2022Review
- Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.Frontiers in immunology · 2022Review
- Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.Cell reports · 2021Article
- T-B Lymphocyte Interactions Promote Type 1 Diabetes Independently of SLAM-Associated Protein.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?Therapeutic advances in endocrinology and metabolism · 2020Review
- Immune cell trafficking to the islets during type 1 diabetes.Clinical and experimental immunology · 2019Review
- Circulating CXCR5Diabetologia · 2019Article
- The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.Cold Spring Harbor perspectives in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lymphocytes that invade nonlymphoid tissues often organize into follicle-like structures known as tertiary lymphoid organs (TLOs). These structures resemble those found in spleen or lymph nodes, but their function is unknown. TLOs are recognized in many autoimmune diseases, including the NOD mouse model of type 1 diabetes. In some cases, TLOs have been associated with the B lymphocyte chemoattractant, CXCL13. Studies presented in this article show that CXCL13 is present in inflamed islets of NOD mice. Ab blockade of this chemokine unraveled B lymphocyte organization in islet TLOs, without reducing their proportion in the islets. These chaotic milieus contained B lymphocytes with the same distinct repertoire of B cell receptors as those found in mice with well-organized structures. Somatic hypermutation, associated with T-B interactions, was not impaired in these disorganized insulitis lesions. Finally, loss of B lymphocyte organization in islets did not provide disease protection. Thus, B lymphocytes infiltrating islets in NOD mice do not require the morphology of secondary lymphoid tissues to support their role in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.